BioLight
Innovation in Ophthalmology

We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome, or DES, and age-related macular degeneration, or AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.

Our goal is to be a leading global ophthalmic company by building a diverse and balanced portfolio of innovative products and product candidates, establishing a sales force to maximize the commercial potential of our products, maintaining a global, diverse network of ophthalmic specialists and accelerating knowledge synergies and innovation. We plan to add products and product candidates to our pipeline by expanding our current platform technologies to additional indications and through in-licensing and investing in new platform technologies, technologies, products and product candidates.

Leading key investors, holding about 55% of BioLight’s issued and outstanding shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel and Rock One A Hong Kong investment based company.

BioLight is a public traded company on the Tel-Aviv Stock Exchange (BOLT).

News